DALLAS, May 5 ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP) announced today that renowned business columnistand author Gene Marcial of BusinessWeek has highlighted Access Pharmaceuticalsin his recently released investing book titled "7 Commandments of StockInvesting." In a section pertaining to his sixth commandment of "not fearingthe unknown," Mr. Marcial includes Access Pharmaceuticals as one of three"unrecognized attractive biotechs" that are not widely followed by Wall Streetbut "whose prospects look tantalizing because of their huge potential value."Included in the analysis is commentary on Access' ProLindac, its proprietarysecond-generation DACH platinum drug that is being developed to target themarkets currently being served by Sanofi-Aventis' Eloxatin, and on MuGard,Access' FDA-approved treatment for oral mucositis. Gene Marcial has beenBusinessWeek's "Inside Wall Street" columnist for the past 26 years, and is aformer columnist at the Wall Street Journal.
ProLindac is a novel DACH platinum prodrug which has been shown to beactive in a wide variety of solid tumors in both preclinical models and inhuman trials. Access believes that ProLindac's unique molecular designpotentially could eliminate some of the toxic side effects seen in thecurrently marketed DACH platinum, Eloxatin, which has sales in excess of$2 billion.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company thatdevelops and commercializes propriety products for the treatment andsupportive care of cancer patients. Access' products include ProLindac(TM),currently in Phase 2 clinical testing of patients with ovarian cancer, andMuGard(TM) for the management of patients with mucositis. The company also hasother advanced drug delivery technologies including Cobalamin(TM)-mediatedtargeted delivery and oral drug delivery, its proprietary nanopolymer deliverytechnology based on the natural vitamin B12 uptake mechanism; Angiolix(R), ahumanized monoclonal antibody which acts as an anti-angiogenesis factor and istargeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activatedin the hypoxic zones of solid tumors to kill cancer cells; Alchemix, achemotherapeutic agent that combines multiple modes of action to overcome drugresistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitorand differentiating agent currently a Phase 2 clinical candidate. Foradditional information on Access Pharmaceuticals, please visit our website athttp://www.accesspharma.com .
This press release contains certain statements that are forward-lookingwithin the meaning of Section 27a of the Securities Act of 1933, as amended,and that involve risks and uncertainties. These statements include thoserelating to: our ability to close the financing transaction, early resultsfrom our clinical trial, Access' plans to continue and initiate clinicaltrials, the value of its products in the market, its ability to achieveclinical and commercial success and its ability to successfully developmarketed products. These statements are subject to numerous risks, includingbut not limited Access' need to obtain additional financing in order tocontinue the clinical trial and operations and to the risks detailed inAccess' Annual Reports on Form 10-K and other reports filed by Access with theSecurities and Exchange Commission.
SOURCE Access Pharmaceuticals, Inc.